Material Event Form 8 K

Item 8.01 Other Events.

On November 22, 2024, revisions to estimates for primary completion and study completion dates related to Alumis Inc.'s (the "Company") LUMUS clinical trial were made available on ClinicalTrials.gov. LUMUS is a global, multicenter, randomized, double-blind, placebo-controlled Phase 2 trial that is designed to evaluate the efficacy, safety and pharmacokinetics of multiple doses of ESK-001 in adult patients with systemic lupus erythematosus (SLE). This information, as updated, conforms with the Company's disclosures in its filings with the Securities and Exchange Commission and previous public guidance. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.